価格表

在庫・価格 : 2025年04月26日 12時54分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Rox Factor IX Kit (2x50tests) <Factor IX, Human, Chromogenic Activity Assay Kit>
データシート※最新のデータシートでない場合があります
900020 ROXロシックス
Rossix AB
1 kit ¥46,000
(未発注)
追加

在庫・価格 : 2025年04月26日 12時54分 現在

Rox Factor IX Kit (2x50tests) <Factor IX, Human, Chromogenic Activity Assay Kit>

  • 商品コード:900020
  • メーカー:ROX
  • 包装:1kit
  • 価格: ¥46,000
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Lengler J et al. Development of an <i>In&#xA0;Vitro</i> Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release. Mol Ther Methods Clin Dev 2020 Jun;17:581-588
Lengler J et al
2020/01/01
PubMed
2 Williams SC et al. Activity measurements of dalcinonacog alfa. Haemophilia 2020 Mar;26(2):346-353
Williams SC et al
2020/01/01
PubMed
3 Ros辿n S et al. FIX potency of rFIX-Albumin fusion protein is underestimated by one-stage methods using silica-based APTT reagents. Haemophilia 2020 Mar;26(2):340-345
Ros辿n S et al
2020/01/01
PubMed
4 Escuriola Ettingshausen C et al. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial. Res Pract Thromb Haemost 2019 Apr;3(2):268-276
Escuriola Ettingshausen C et al
2019/01/01
PubMed
5 Kershaw GW et al. Evaluation of chromogenic factor IX assays by automated protocols. Haemophilia 2018 May;24(3):492-501
Kershaw GW et al
2018/01/01
PubMed
6 Tiefenbacher S et al. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol. J Thromb Haemost 2017 10;15(10):1901-1912
Tiefenbacher S et al
2017/01/01
PubMed
7 DeRosa F et al. Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther. 2016 Oct;23(10):699-707
DeRosa F et al
2016/01/01
PubMed
8 Ros辿n P et al. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J Thromb Haemost 2016 07;14(7):1420-7
Ros辿n P et al
2016/01/01
PubMed
9 Bowyer AE et al. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study. J Thromb Haemost 2016 07;14(7):1428-35
Bowyer AE et al
2016/01/01
PubMed
10 Gray E, Hogwood J, Dougall T, Rigsby P. Collaborate study report on blood coagulation factor IX. Value assignment of the 5th International Standard for Blood Coagulation Factor IX Concentrate and the 3rd Ph Eur BRP for human Factor IX Concentrate. WHO 201

PubMed
  • No.: 1
  • 文献情報:
    Lengler J et al. Development of an <i>In&#xA0;Vitro</i> Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release. Mol Ther Methods Clin Dev 2020 Jun;17:581-588
    Lengler J et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Williams SC et al. Activity measurements of dalcinonacog alfa. Haemophilia 2020 Mar;26(2):346-353
    Williams SC et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Ros辿n S et al. FIX potency of rFIX-Albumin fusion protein is underestimated by one-stage methods using silica-based APTT reagents. Haemophilia 2020 Mar;26(2):340-345
    Ros辿n S et al
    2020/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Escuriola Ettingshausen C et al. Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial. Res Pract Thromb Haemost 2019 Apr;3(2):268-276
    Escuriola Ettingshausen C et al
    2019/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Kershaw GW et al. Evaluation of chromogenic factor IX assays by automated protocols. Haemophilia 2018 May;24(3):492-501
    Kershaw GW et al
    2018/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Tiefenbacher S et al. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol. J Thromb Haemost 2017 10;15(10):1901-1912
    Tiefenbacher S et al
    2017/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    DeRosa F et al. Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther. 2016 Oct;23(10):699-707
    DeRosa F et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Ros辿n P et al. Overestimation of N-glycoPEGylated factor IX activity in a one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX. J Thromb Haemost 2016 07;14(7):1420-7
    Ros辿n P et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Bowyer AE et al. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study. J Thromb Haemost 2016 07;14(7):1428-35
    Bowyer AE et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Gray E, Hogwood J, Dougall T, Rigsby P. Collaborate study report on blood coagulation factor IX. Value assignment of the 5th International Standard for Blood Coagulation Factor IX Concentrate and the 3rd Ph Eur BRP for human Factor IX Concentrate. WHO 201

  • 備考:
  • 参照:
    PubMed